SYNTHESIS, SPECTRAL CHARACTERIZATION, AND ANTIPROLIFERATIVE ACTIVITY OF DISPIROPYRROLIDINES CONTAINING 2-THIOXOTHIAZOLIDIN-4-ONE NUCLEUS

Authors

  • SIVAGNANAM JAYASURIYA Departmnent of Chemistry, Karpagam Academy of Higher Education, Coimbatore, Tamil Nadu, India.
  • THALIGAI SUBRAMANIAN MALARVIZHI Department of General Engineering, Muthiah Polytechnic College, Chidambaram, Tami Nadu, India.
  • STEPHENKUMAR CELESTINA Departmnent of Chemistry, Karpagam Academy of Higher Education, Coimbatore, Tamil Nadu, India.
  • KAVERI SUNDARAM Departmnent of Chemistry, Karpagam Academy of Higher Education, Coimbatore, Tamil Nadu, India.

DOI:

https://doi.org/10.22159/ajpcr.2019.v12i5.32902

Keywords:

Rhodanine, Acenaphthenequinone, Sarcosine, Antiproliferative activity

Abstract

Objective: Spiro compounds are present in nature, endowed with deep biological activities. Heterocyclic compounds with a pyrrolidine scaffold are one of the paradigms of organic chemistry that exhibits a wide variety of properties and biological functions. Based on these, seven dispiropyrrolidines have been accomplished by [3+2] cycloaddition reaction from acenaphthenequinone and sarcosine with several dipolaro files such as substituted 5-benzylidene-2-thioxothiazolidin-4-ones.

Methods: Cycloadducts 4a-g were prepared by conventional method and the structures of the compounds 4a-g were completely characterized by infrared, 1H, 13C nuclear magnetic resonance spectral data, and elemental analysis. The cytotoxic activity of the synthesized compounds was carried out by 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide assay.

Results: The dispiropyrrolidines 4a-g were showed a moderate-to-good cytotoxic activity against human cervical cancer lines. Among all the synthesized compounds, 4d was found to be more potent with human cervical cancer line with an half maximal inhibitory concentration (IC50) value of 5.5 μM.

Conclusion: The synthesized compound 4d found to be an excellent activity which is nearly closed to reference drug gemcitabine with an IC50 value of 4.6 μM.

Downloads

Download data is not yet available.

References

Padwa A. In: 1,3-Dipolar Cycloaddition Chemistry. Vol. 1 and 2. New York: Wiley; 1984.

Raj AA, Raghunathan R. A novel entry into a new class of spiroheterocyclic framework: Regioselective synthesis of dispiro [oxindole-cyclohexanone] pyrrolidines and dispiro [oxindole-hexahydroindazole] pyrrolidines. Tetrahedron 2001;57:10293-8.

Galliford CV, Scheidt KA. Pyrrolidinyl-spirooxindole natural products as inspirations for the development of potential therapeutic agents. Angew Chem Int Ed Engl 2007;46:8748-58.

Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A, et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 2018;68:394-424.

Song MX, Zheng CJ, Deng XQ, Wang Q, Hou SP, Liu TT, et al. Synthesis and bioactivity evaluation of rhodanine derivatives as potential anti-bacterial agents. Eur J Med Chem 2012;54:403-12.

Pooja P, Meenakshi D, Amol K, Ganesh N, Smita P. Design, synthesis, docking studies and biological evaluation of 2-phenyl-3-(substituted benzo[d] thiazol 2-ylamino)-quinazoline-4(3h)-one derivatives as antimicrobial agents. Int J Pharm Pharm Sci 2018;10:57-61.

Khan FA, Sangshetti JN. Design, synthesis and molecular docking study of hybrid quinoline-4-yloxadiazoles/oxathiadiazoles as potent antifungal agents. Int J Pharm Pharm Sci 2015;7:222-9.

Wu JH, Wang XH, Yi YH, Lee KH. Anti-AIDS agents 54. A potent anti-HIV chalcone and flavonoids from genus desmos. Bioorg Med Chem Lett 2003;13:1813-5.

Kumar G, Parasuraman P, Sharma SK, Banerjee T, Karmodiya K, Surolia N, et al. Discovery of a rhodanine class of compounds as inhibitors of plasmodium falciparum enoyl-acyl carrier protein reductase. J Med Chem 2007;50:2665-75.

Inamori Y, Okamoto Y, Takegawa Y, Tsujibo H, Sakagami Y, Kumeda Y, et al. Insecticidal and antifungal activities of aminorhodanine derivatives. Biosci Biotech Biochem 1998;62:1025-7.

Won SJ, Liu CT, Tsao LT, Weng JR, Ko HH, Wang JP, et al. Synthetic chalcones as potential anti-inflammatory and cancer chemopreventive agents. Eur J Med Chem 2005;40:103-12.

Murugan R, Anbazhagan S, Lingeshwaran, Narayanan SS. Synthesis and in vivo antidiabetic activity of novel dispiropyrrolidines through [3+2] cycloaddition reactions with thiazolidinedione and rhodanine derivatives. Eur J Med Chem 2009;44:3272-9.

Cutshall NS, O’Day C, Prezhdo M. Rhodanine derivatives as inhibitors of JSP-1. Bioorg Med Chem Lett 2005;15:3374-9.

Carter PH, Scherle PA, Muckelbauer JK, Voss ME, Liu RQ, Thompson LA, et al. Photochemically enhanced binding of small molecules to the tumor necrosis factor receptor-1 inhibits the binding of TNF-alpha. Proc Natl Acad Sci U S A 2001;98:11879-84.

Degterev A, Lugovskoy A, Cardone M, Mulley B, Wagner G, Mitchison T, et al. Identification of small-molecule inhibitors of interaction between the BH3 domain and bcl-xL. Nat Cell Biol 2001;3:173-82.

Helal CJ, Sanner MA, Cooper CB, Gant T, Adam M, Lucas JC, et al. Discovery and SAR of 2-aminothiazole inhibitors of cyclin-dependent kinase 5/p25 as a potential treatment for alzheimer’s disease. Bioorg Med Chem Lett 2004;14:5521-5.

Sundaram K, Ravi S. Synthesis, antibacterial activity against MRSA, and in vitro cytotoxic activity against HeLa cell lines of novel 3-?-carboxy ethyl-5-benzylidene rhodanine derivatives. Res Chem Intermed 2015;41:1011-21.

Thangamani A. Regiospecific synthesis and biological evaluation of spirooxindolopyrrolizidines via [3+2] cycloaddition of azomethine ylide. Eur J Med Chem 2010;45:6120-6.

Mosmann T. Rapid colorimetric assay for cellular growth and survival: Application to proliferation and cytotoxicity assays. J Immunol Methods 1983;65:55-63.

Published

07-05-2019

How to Cite

SIVAGNANAM JAYASURIYA, T. S. . MALARVIZHI, STEPHENKUMAR CELESTINA, and KAVERI SUNDARAM. “SYNTHESIS, SPECTRAL CHARACTERIZATION, AND ANTIPROLIFERATIVE ACTIVITY OF DISPIROPYRROLIDINES CONTAINING 2-THIOXOTHIAZOLIDIN-4-ONE NUCLEUS”. Asian Journal of Pharmaceutical and Clinical Research, vol. 12, no. 5, May 2019, pp. 313-6, doi:10.22159/ajpcr.2019.v12i5.32902.

Issue

Section

Original Article(s)